Should I buy Cardinal Health (CAH) stock or is it too late?

Cardinal Health · Health Care · price $235

See the full Cardinal Health (CAH) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Morgan Stanley — 69% of its targets hit on this sector (825 calls tested). It aims for $265 (+13 %), call made on August 13, 2026, maturing on August 13, 2027 (15 d ago).

The 10 reliable analysts $275+17 %

The 2 other firms $273+16 %

How to read it: the 10 reliable firms are not filtered by optimism — 10 aim above the price, 0 below, hence their $275 median. “The 2 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Cardinal Health

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Evercore ISI Group	83 %	+37.0 %	6	$270 +15%
Baird	88 %	+36.7 %	8	$274 +17%
B of A Securities	89 %	+34.2 %	9	$260 +11%
Morgan Stanley	95 %	+34.1 %	20	$265 +13%
UBS	93 %	+31.4 %	15	$280 +19%
Barclays	86 %	+21.0 %	14	$275 +17%
Wells Fargo	40 %	-1.7 %	5	$277 +18%
Credit Suisse	100 %	+29.6 %	8	—

In short — Should you invest in Cardinal Health? Is it too late, still worth it? Analysts are overwhelmingly positive (92% buy, median target $275, i.e. +17%), and the most reliable on CAH targets even higher. But the valuation is stretched (P/E ~33). We give you both sides, with the numbers — not advice.

✅ Reasons to believe

92% of analysts rate it a buy (Buy consensus, 13 ratings) — a sign of market conviction.
Median price target $275, i.e. +17% from the current price ($235).
The most reliable firm on CAH, Morgan Stanley (95% hit rate, 20 scored calls), targets $265 (call made on August 12, 2026, maturing on August 12, 2027) (+13%) in its most recent call, and $245 (call made on January 29, 2026, maturing on January 29, 2027) (+4%) in the one coming due soonest.
9 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 13 ratings, 1 is neutral.
High valuation (P/E ~33): strong growth is already "priced in", leaving little room for error.
A 12-month target is not a guaranteed path: the price can fall in the meantime.

The analyst consensus on CAH

Median target $275 (+17%) · 13 ratings · Buy consensus

Strong Buy00%

Buy1292%

Hold18%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Cardinal Health now?

We won't decide for you. The facts: 92% of analysts rate it a buy, median target $275 (+17%), and Morgan Stanley (most reliable on CAH, 95%) targets $265. Weigh that against valuation (P/E ~33). This is not personalized advice.

Is it too late to invest in Cardinal Health?

Not according to analysts: the median target ($275) is still +17% above the current price ($235) (most reliable on CAH: Morgan Stanley, 95%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Cardinal Health still worth investing in?

It depends on the gap between the price ($235) and its estimated value: analysts target $275 on median (+17%), with 92% buys (most reliable on CAH: Morgan Stanley, 95%). Cross-check with their real reliability on CAH and the cautions above. Information, not advice.

What's the main risk in buying CAH?

The consensus is not unanimous: of 13 ratings, 1 is neutral.

→ Go deeper: the full Cardinal Health profile (consensus, analyst reliability, price target, performance).